Leticia Toledo-Sherman
Corporate Officer/Principal bei LymphoSign, Inc.
Profil
Leticia Toledo-Sherman has been Executive Director of Chemistry for LymphoSign, Inc. since August 2004.
Prior to joining LymphoSign, Inc, she was Director of Drug Design and Discovery for MDS Proteomics Inc. Dr. Toledo-Sherman worked for Kinetix Pharmaceuticals, Inc. She received a PhD in Organic Chemistry from The State University of New York.
Aktive Positionen von Leticia Toledo-Sherman
| Unternehmen | Position | Beginn |
|---|---|---|
LymphoSign, Inc.
 LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Corporate Officer/Principal | 01.08.2004 |
Ehemalige bekannte Positionen von Leticia Toledo-Sherman
| Unternehmen | Position | Ende |
|---|---|---|
| MDS Proteomics, Inc. | Corporate Officer/Principal | - |
Kinetix Pharmaceuticals, Inc.
 Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Corporate Officer/Principal | - |
Ausbildung von Leticia Toledo-Sherman
| The State University of New York | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
| MDS Proteomics, Inc. | Commercial Services |
Kinetix Pharmaceuticals, Inc.
Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Commercial Services |
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Health Technology |
